Clinical Trial Update: A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating YL-13027 in combination with gemcitabine and Nab-paclitaxel in patients with refractory metastatic pancreatic cancer has been terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• YL-13027

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Pancreatic Cancer | Phase 1 | Status: TERMINATED